Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

CNBC

Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update

EconomyDaily Composite
ShareXFacebook

Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.

C

Source

CNBC

Read full article at CNBC

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement